<DOC>
	<DOCNO>NCT00806572</DOCNO>
	<brief_summary>This phase II study examine clinical immunological effect humanize FcR non-binding anti-CD3 mAb participant Type 1 diabetes mellitus ( T1DM ) , develop therapy prevent immune destruction lead β cell loss .</brief_summary>
	<brief_title>Treatment With hOKT3gamma1 ( Ala-Ala ) T1DM</brief_title>
	<detailed_description>This 2-arm , open-label phase II trial involve 0 3 cycle treatment 6 month apart hOKT3γ1 ( Ala-Ala ) , first year disease participants new onset T1DM . Each cycle consist 12 daily dos hOKT3γ1 ( Ala-Ala ) . Participants randomize ratio 2:1 either experimental arm control arm stratify study site . To eligible , participant must : male female 7-30 year age , diagnose T1DM within past 6 week , body weight ≥26 kg time enrollment detectable anti-GAD , anti-ICA512/IA-2 , insulin autoantibody ( participant insulin ≤10 day ) . Participants randomize experimental group start first cycle hOKT3γ1 ( Ala-Ala ) within 4-8 week T1DM diagnosis . Each participant randomize experimental group receive 3 cycle drug treatment , separate 6 month . Each cycle consist 12 day drug treatment . Both group undergo Mixed Meal Stimulated C-Peptide Test receive blood draw mechanistic study schedule .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>diagnose T1DM within past 6 week body weight ≥26 kg time enrollment detectable antiGAD , antiICA512/IA2 , insulin autoantibody ( participant insulin ≤10 day ) . Pregnant lactating female ; Prior OKT3 treatment ; Known hypersensitivity murine product ; Uncompensated heart failure fluid overload , recent myocardial infarction ; History epilepsy , cancer , active infection , atopic disease , active Grave 's disease , cystic fibrosis , sickle cell anemia , neuropathy , peripheral vascular disease , cerebrovascular disease , concurrent autoimmune disease , asthma ; Any medical condition opinion investigator interfere safe completion trial ; Inability give informed consent ; Prior participation clinical trial could potentially affect diabetes immunologic status ; Participation clinical trial within last 6 week ; HIV positive ; Positive Hepatitis B surface antigen AntiHepatitis C antibody ; Seropositivity Toxoplasmosis ( IgG ) ; Lymphopenia ( &lt; 1000 lymphocytes/microliter ) ; Thrombocytopenia ( &lt; 150,000/mm3 platelet ) ; Anemia ( Hgb &lt; 10g/dL ) ; Vaccination live virus within past 6 week ; Positive PPD skin test ; Any infectious mononucleosislike illness within 3 month prior enrollment ; Serologic evidence acute infection EBV CMV base test list defined protocol .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes , juvenile diabetes , teplizumab</keyword>
</DOC>